[et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”OptiRiMox Press Release” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-content\/uploads\/sites\/50\/2024\/06\/OptiRiMox-Logo.jpg” title_text=”OptiRiMox Logo” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_image][et_pb_heading title=”Strengthening Clinical trial Capacity Development in Tanzania, Malawi, Gabon & Mozambique” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
OptiRiMoxTB \u2013 An international pragmatic trial with Opti<\/strong>mised dose of Ri<\/strong>fampicin and Mox<\/strong>ifloxacin for the treatment of drug susceptible pulmonary tuberculosis (TB<\/strong>)<\/p>\n The OptiRiMoxTB clinical trial is part of SimpliciTB programme, which includes an international clinical trial and supports the development of capacity in the network of African clinical trial sites.\u00a0 The grant is funded by the EDCTP2 Programme (grant number RIA2017S-2012).<\/p>\n The OptiRiMoxTB trial is being sponsored and led by the team at Kibong\u2019oto Infectious Disease Hospital, KIDH in Tanzania. Dr Stella Mpagama is the Principal Investigator and a Senior EDCTP Fellow and honorary member of staff at the University of St Andrews. The KIDH and wider team are supported and mentored by University of St Andrews, who are also providing support to Dr Hamu Mlyuka an EDCTP Clinical Research and Product Development Fellow from Muhimbili University of Health and Allied Sciences, Tanzania also working for the trial.\u00a0 Long established partners, National Institute for Medical Research Mbeya Medical Research Centre, Mwanza Medical Research Centre, Kilimanjaro Clinical Research Institute and Ifakara Health Institute, Tanzania, University College London, Radboud University Medical Centre, Netherlands and TB Alliance are also supporting the sites.<\/p>\n The capacity development aspect of the trial aims to allow new TB trial sites so that they can perform therapeutic clinical trials. The new sites are Kamazu University of Health Sciences KUHeS, Malawi, Centres de Recherches M\u00e9dicales de Lambar\u00e9n\u00e9 De Sa\u00fade, INS, Mozambique.<\/p>\n OptiRiMoxTB is an important development that will test an easy to implement shorter regimen that emerges from our programme of research.\u00a0 It will test whether a 4-month therapy based on Rifampicin (35mg\/kg) +\/- Moxifloxacin (400mg) is non-inferior to conventional 6-month DS-TB therapy.\u00a0 It is anticipated the trial will recruit 414 patients.<\/p>\n All 4 trial sites are now recruiting participants, having successfully recruited over 50% and are due to complete recruitment in August 2024.\u00a0 The sites have had many challenges to overcome throughout the clinical trial preparation phase.<\/p>\n If successful the OptiRiMoxTB regimen will allow individuals with-drug susceptible tuberculosis to be treated with well-established antibiotics in just four months, saving time money and reducing the burden on patients with this disease.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" OptiRiMoxTB \u2013 An international pragmatic trial with Optimised dose of Rifampicin and Moxifloxacin for the treatment of drug susceptible pulmonary tuberculosis (TB) The OptiRiMoxTB clinical trial is part of SimpliciTB programme, which includes an international clinical trial and supports the development of capacity in the network of African clinical trial sites.\u00a0 The grant is funded […]<\/p>\n","protected":false},"author":159,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6682","post","type-post","status-publish","format-standard","hentry","category-uncategorised"],"publishpress_future_action":{"enabled":false,"date":"2026-07-10 10:23:39","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/posts\/6682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/users\/159"}],"replies":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/comments?post=6682"}],"version-history":[{"count":0,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/posts\/6682\/revisions"}],"wp:attachment":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/media?parent=6682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/categories?post=6682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/tags?post=6682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}